The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.25
Bid: 15.00
Ask: 15.50
Change: -0.50 (-3.23%)
Spread: 0.50 (3.333%)
Open: 15.00
High: 15.50
Low: 14.65
Prev. Close: 15.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commercial Sale

31 Jan 2007 07:02

Angle PLC31 January 2007 For Immediate Release 31 January 2007 ANGLE plc ('ANGLE' or 'the Company') First Commercial Sale of Synature Product ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce that its Progeny(R)venture company Synature, which offers a new and innovative approach to onlinemarketing, has secured its first commercial sale with a leading player in theworld's most active markets for package holidays and other leisure travelservices. Together they have launched Holiday Matchmaker, a new way for holidaybuyers to find their ideal destination based on recommendations from like-mindedpeople. This is the first commercial sale of Synature's unique patentedtechnology qubox(TM). Holiday Matchmaker utilises Synature's "attitudinal matching" approach todevelop principles derived from constructivist psychology to measure a person'sfeelings on a particular subject - in this case holidays - and thereby connectweb users to relevant content. Feelings are measured in a fun, engaging wayusing Synature's unique proprietary technology qubox(TM), to complete an online'questionnaire'. The results are then processed with state-of-the-art patternrecognition algorithms, derived from research at the University of Cambridge,UK, to provide personalised recommendations. Thousands of users of the customer's website have taken part in a surveyspecifically designed for the launch of the Holiday Matchmaker, which providesrecommendations based entirely on the opinions of an "online jury". The recommendation system uses a scientific measure of like-mindedness to ensurea client's holiday suggestions come from people with compatible views. Thesystem provides suggestions in multiple categories, including "essential picks","dream holidays" and "quirky choices". John Woods, Chief Executive of Synature, commented: "The Holiday Matchmaker is a new way of searching for a travel product. Itsresults are based on the unbiased opinions of a like-minded peer group. Whereasprevious generations of search and personalisation technology have struggledwith complex products such as travel, our approach built on like-mindedness andusing the power of the social internet takes this product complexity in itsstride. We can even tackle hypothetical questions, such as the idea ofrecommending a 'dream holiday'." Andrew Newland, Chief Executive of ANGLE plc, added: "We are delighted that Synature has secured its first commercial sale with aleading player in the holiday market. The Synature qubox(TM)technology has wideapplication in many online markets and we look forward to further developments." For further information ANGLE plc +44 (0)1483 295830Andrew Newland, Chief Executive Synature +44 (0)8701 909550John Woods, Chief Executive Buchanan Communications +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors: About Synature Synature (www.synature.com) was created by ANGLE in early 2005 to commercialiseintellectual property developed by a Cambridge-based team which offers a newapproach to online target marketing. The company has developed this"attitudinal matching" approach into an ASP service offering advanced socialsearch functionality usable by all types of website including e-commerce, socialnetworks, portals and content sites. About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from offices inthe UK, the US and the Middle East. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSResearch confirms high performance of Parsortix
12th Jan 20217:00 amRNSChange of Auditor
5th Jan 20217:00 amRNSIssue of Equity
9th Dec 20207:00 amRNSParsortix can capture single cancer cell in sample
20th Nov 20204:18 pmRNSHolding(s) in Company
18th Nov 20204:51 pmRNSHolding(s) in Company
13th Nov 202010:46 amRNSResult of General Meeting
3rd Nov 20202:54 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSInterim Results
27th Oct 20206:28 pmRNSResult of Placing & Notice of General Meeting
27th Oct 20207:00 amRNSAccelerated bookbuild to raise up to £20m
20th Oct 20207:00 amRNSSubmission accepted by FDA for substantive review
28th Sep 20207:00 amRNSIssue of LTIP Options and Share Options
28th Sep 20207:00 amRNSANGLE announces completion of FDA submission
23rd Sep 20207:00 amRNSPotential treatment strategy to limit metastasis
11th Sep 20203:35 pmRNSHolding(s) in Company
11th Sep 20203:30 pmRNSHolding(s) in Company
2nd Sep 20201:49 pmRNSNotification of Interim Results and Webcast
2nd Sep 202010:00 amRNSHolding(s) in Company
27th Aug 20203:13 pmRNSResult of 2020 Annual General Meeting
18th Aug 20209:30 amRNSHolding(s) in Company
14th Aug 20207:00 amRNSParsortix use to assess response to immunotherapy
6th Aug 202012:20 pmRNSHolding(s) in Company
5th Aug 20207:00 amRNSNotice of AGM and Posting of Annual Report
20th Jul 20207:00 amRNSStudy: Parsortix use in metastatic breast cancer
8th Jul 20205:35 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
25th Jun 20207:00 amRNSPreliminary Results
22nd Jun 20207:00 amRNSBlood donations recommenced for FDA studies
29th May 20207:00 amRNSNotice of Results
12th May 20207:00 amRNSCTC potential as biomarker in MET inhibitor trials
4th May 20207:00 amRNSLeading cancer centre publishes Parsortix workflow
28th Apr 20207:00 amRNSBusiness Update
17th Apr 20207:00 amRNSParsortix performance in head and neck cancer
3rd Mar 20207:00 amRNSAssessing risk of brain metastasis in lung cancer
27th Feb 20207:00 amRNSParsortix outperforms other CTC systems in RCC
25th Feb 20207:00 amRNSANGLE announce Tri-Con presentation with BioView
17th Feb 20207:00 amRNSData demonstrates key advantages of Parsortix
11th Feb 20207:00 amRNSStudy demonstrates Parsortix potential in melanoma
3rd Feb 20209:10 amRNSIssue of Equity
30th Jan 20207:00 amRNSInterim Results
30th Jan 20207:00 amRNSChange of accounting reference date
22nd Jan 20207:00 amRNSSuccessful face-to-face meeting with FDA
8th Jan 202012:33 pmRNSNotice of Results
23rd Dec 20199:55 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.